Dermatology

At Maui Derm NP+PA Summer 2026, Matthew Zirwas, MD, shares cases of a factory worker with PPD allergy and a chronic spontaneous urticaria patient with persistent facial dermatitis.

Matthew Zirwas, MD, on why adult-onset atopic dermatitis is the most undertreated condition in dermatology and how diagnostic criteria are driving years of delayed care.

Dawn Eichenfield, MD, discusses off-label treatment rationale, biologics, JAK inhibitors, and care gaps in rare pediatric skin conditions.

Donna Culton, MD, PhD, explains why autoimmune blistering diseases often look nothing like the textbook and how to pursue the diagnosis anyway.

Stefan Weiss, MD, on recognizing mast cell disorders in the dermatology clinic and how avapritinib is reshaping treatment for indolent systemic mastocytosis.

The topic of precision medicine in dermatology is explored in this segment of Bunick's interview at RAD 2026.

Dawn Eichenfield, MD, PhD, discusses differential diagnosis, off-label treatment rationale, and multidisciplinary care for rare and atypical skin conditions in children.

This interview at RAD highlights FDA-approved therapies in the atopic dermatitis treatment armamentarium.

Matthew Zirwas, MD, explains why topical JAK inhibitors represent a clinical turning point for hand eczema.

This June episode of the podcast highlights one clinicians journey and experiences as a woman physician in the dermatology and rheumatology fields.

Matthew Zirwas, MD, on using dupilumab and lebrikizumab to guide patch testing decisions and the 2 most missed allergens in eczematous disease.

In the latest Skin of Color Savvy episode, Umayr Shaikh, MPH, shares how his work is shaping his medical career.

Siegfried discusses some of the most notable highlights of her session at the RAD 2026 conference regarding clinical pearls in dermatology.

HCPLive previews Maui Derm NP+PA Summer 2026, covering sessions on atopic dermatitis, acne, psoriasis, pigmentation disorders, and more.

This segment of Lio's RAD Conference interview in Nashville highlights the growing number of therapeutics and an increasingly personalized approach.

Peter Lio, MD, spoke at the RAD 2026 conference about the upcoming AAD pediatric guidelines for atopic dermatitis.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema.

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Nguyen urges clinicians to consider patient's disease presentation, comorbidities, treatment goals, and preferences when making therapeutic decisions.

At RAD 2026, Nguyen speaks on key highlights from his “Medical Crossfire” session, touching on the atopic dermatitis treatment landscape.